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INTRODUCTION
The risks of hepatocellular carcinoma (HCC) can increase
due to the progression of chronic hepatitis to hepatic cirrho-
sis in patients with chronic hepatitis C virus (HCV) disease
(1). The 5-yr follow-up study revealed that the incidence of
HCC was approximately 37% among the HCV associated
cirrhosis patients (2). In spite of the development of advanced
therapies including transcatheter arterial embolization and
percutaneous ethanol injection, high recurrence and poor
prognosis are frequently observed in HCC patients. Accord-
ing to the Osaka Cancer Registry, Japan, in 1987 the 5-yr
relative survival rate of HCC patients was considerably low
(5.5%). Thus, in order to improve the prognosis of chronic
HCV disease patients, who are a high-risk group of HCC,
the prevention of HCC development is particularly impor-
tant as well as periodical check-ups for early detection.
For thousands of years, ginseng has been used as a tonic
and nutrient in Asian countries. Ginseng has been shown to
improve one’ s general condition and non-specific complaints
due to exhaustive and feverish illnesses through enhancement
of one s natural healing power. Also, ginseng has been shown
to inhibit carcinogenesis in animal models (3, 4). Nishino
(5) found that ginseng significantly inhibited the develop-
ment of spontaneous liver tumors in C3H/He male mice. A
recent case-control study in Korea (6, 7) demonstrated the
prevention of cancer development in several organs by gin-
seng ingestion.
Ginseng is formulated in a variety of medicines and Sho-
saiko-to is one of the well-known Kampo medicines that
contains ginseng. The intervention study using Sho-saiko-
to suggested that it could prevent the development of HCC
in chronic hepatitis patients (8). Regrettably, this medicine
has been reported to cause a severe side effect, interstitial
pneumonia, however, it is believed that ginseng did not
contributes to this side effect. Therefore, we planned a multi-
center, double-blind, randomized controlled trial to deter-
mine the preventive effect of ginseng on HCC in chronic
HCV disease patients who are a high risk group of HCC.
MATERIALS AND METHODS
This intervention study will be conducted at 8 hospitals
including Toyonaka Municipal Hospital, Izumiotu Munici-
pal Hospital, Izumisano Municipal Hospital, Suita Munici-
pal Hospital, Kawanishi City General Hospital, Otemae
Hospital, Ikeda Municipal Hospital and National Shikoku
Cancer Center.
Inclusion Criteria
The subjects should be chronic HCV disease patients, such
as those with chronic hepatitis and cirrhosis, and be negative
for hepatitis B surface antigen and positive for HCV anti-
body or HCV-RNA. L-aspartate:2-oxaloglutarate amino-
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Study on Chemoprevention of Hepatocellular Carcinoma by Ginseng:
An Introduction to the Protocol
In patients with chronic hepatitis C virus disease, there is a high incidence of
development of hepatocedllular carcinaoma (HCC) in the process of transition
from chronic hepatitis to hepatic cirrhosis. Although ginseng traditionally has
been used mainly as a nutritional supplement in Asian countries, a case-control
study found that it may inhibit the development of HCC. We therefore planned a
clinical study of HCC prevention by medicinal ginseng. The subjects are patients
with chronic C virus disease (chronic hepatitis and hepatic cirrhosis), who are
high risk group for HCC. This intervention study is a multi-center, double-blind,
randomized controlled trial. The participants will be randomly divided into two
groups. The test sample (1 g of red ginseng powder per day) will be adminis-
tered for 5 yr, and ginseng intake will be prohibited during the administration
period. The primary endpoint of this study is the development of HCC. Target
number of recruiting subjects are 300. The participants should be registered
from February 2001 to January 2003.
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ferase (ALT) in the chronic hepatitis patients should be out
of the normal range. In hepatic cirrhosis patients, ALT and
AST should be out of the normal range or conclusively diag-
nosed for hepatic cirrhosis with an abdominal ultrasonograph
or histological examination. In the chronic hepatitis patients
who were administered with interferon, disappearance of
virus and normalization of ALT and AST should not be ob-
served during the one-year follow-up after the interferon treat-
ment. The patients who are not treated with interferon can
be enrolled, however, the precise explanation as to why the
patients are not on interferon therapy should be noted. Sub-
jects who receive interferon therapy after enrolling in this
study should be excluded as a dropout case. Hepatic cirrho-
sis patients, classified as being in Compensated hepatic cir-
rhosis (Child A), can be eligible for the study. After a full ex-
planation of the details of the study in writing, patients over
40 who have signed the Agreement can be eligible.
Exclusion Criteria
Patients with the following criteria will be excluded: 1) those
with a platelet count greater than 150 thousand/ L, 2) those
who may be re-administered interferon, 3) those allergic to
medicines and/or herbs, 4) current ginseng users who will
not discontinue its use, 5) those with a history of malignant
neoplasms or current cancer patients, 6) those who will be
unable to comply with periodical follow-ups, including an
abdominal ultrasonography, and 7) those who are one-time
participants of this study.
Recruiting and entry procedures, and sample admin-
istration
This intervention study is a multi-center, double-blind,
randomized placebo-controlled trial. When collaborator-
physicians examine patients who meet the inclusion criteria,
they will ask them to participate in this study. After agree-
ing to participate in the study, the patients will sign the
Agreement (informed consent). The physicians will fill out
the  “Case Card” , and mail it to the secretariat of the study
(Osaka Medical Center for Cancer and Cardiovascular Dis-
eases). As soon as the secretariat receives the consent forms,
they will register the patient as a participant.
The participants will be randomly divided into two groups:
red ginseng administered group (GI group) and non-func-
tional food administered group (NF group), using the cate-
gorized Block-Random methods according to the progres-
sion of chronic hepatitis (history of interferon therapy, and
hepatic cirrhosis) and hospitals where the participants are
recruited. A secretary will register the assignment of partic-
ipants and inform Wakunaga Pharmaceutical Co., Ltd. A
co-researcher of Wakunaga Pharmaceutical Co., Ltd. will
send a test sample and a diary for recording sample inges-
tion to each participant every 3 months. The test sample will
be administered for 5 yr, and ginseng intake will be prohib-
ited during the administration period.
Endpoint and examinations
The primary endpoint of this study is the development of
HCC. An abdominal ultrasonography will be performed
before and after starting the ingestion of the samples, and
every 6 months during the intervention. An abdominal
dynamic computed tomography will also be performed
before and after starting the ingestion of the samples, and
once every year during the intervention. Hepatitis C virus
markers, hematological tests, biochemical tests, hemostasis
and coagulation tests, serum  -fetoprotein and serum PIVKA-
II will be regularly determined at a certain period.
In order to confirm compliance, the participants should
record daily the ingested capsule number on a designated
form, and the bottle containing a 3-month supply of test
samples will be collected after its use. Once a year, 20 par-
ticipants will be randomly selected from each group and
their urine will be collected and urinary content of 20(S)-
protopanaxatriol, an aglycone of a major saponin in red gin-
seng, will be determined using GC-MS.
Ethics committees
This study was approved by the following ethics commit-
tees:  “the Ethics and Data Monitoring Committee” for this
study, the ethics committee of Osaka Medical Center for Can-
cer and Cardiovascular Diseases, wherein the secretariat of
the study is set, and the ethics committee of each hospital
wherein the subjects will be recruited.
Target number of recruiting subjects
Three hundred participants (150 per group) will be recruit-
ed for this study and the number of participants should not
be less than 200. The number of participants for determin-
ing the preventive impacts of red ginseng on HCC will be
evaluated based on the following. The annual incidence of
HCC could be 3.5% in chronic hepatitis patients whom the
interferon treatment was not successful and 6% in hepatic
cirrhosis patients, respectively. If the same number of chron-
ic hepatitis patients and hepatic cirrhosis patients partic-
ipate in this study, the average incidence of HCC would be
4.75%. According to the case-control studies conducted by
Yun, cancer preventive efficacy of ginseng was odds ratio
(OR)=0.56 in the 1990’ s study (6), and OR =0.50 in total
and OR=0.48 in the liver in the 1995’ s study (7). Further-
more, Nishino (5) reported that ginseng inhibited the devel-
opment of spontaneous liver tumors in C3H/He male mice
at 0.31. Thus, we estimated that the preventive effect of gin-
seng would be in the hazard ratio of 0.3 to 0.5. On assump-
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are required in order to obtain a significant effect of a p value
less than 0.05 so that the minimum number of participants
cannot be less than 100 in each group and is desirably 150.
The participants should be registered from February 2001
to January 2003.
Evaluation methods
The date of HCC development will be settled on the day
when HCC is first detected by a physician through an abdom-
inal ultrasonography or an abdominal dynamic computed
tomography. The individual prevention period of HCC in
participants will be determined between the date of assign-
ment and the date of HCC development. In participants
without detectable HCC development after 5 yr from the
assigning date, their participation in this study will be cen-
sored at the end of the follow-up. If the participants die of
another disease or by accident, their participation will be
closed at the date of death. Participants who cannot be fol-
lowed up will be managed as dropout cases.
The preventive effects of red ginseng on HCC will be pri-
marily evaluated from the prevention period obtained from
all registered participants using the intent-to-treat principle.
Also, the prevention period obtained from participants who
meet all requirements and have good compliance records will
be evaluated.
The participants will be classified into two categories, chron-
ic hepatitis and liver cirrhosis, and the cumulative incidence
of HCC development in both categories will be separately
estimated using the Kaplan-Meier methods. The estimated
cumulative incidences will be analyzed using the staratified
Logrank test (two sided). If unbalances of prognostic factors
were seen between treatment groups, the stratified propor-
tional hazard models will be used to adjust the effect of con-
founding. The potential confounding factors will be deter-
mined through the background knowledge and preliminary
analyses. The effect measure (Hazard ratio) of ginseng on HCC
prevention will be estimated as the point estimate with 90
and 95% confidence intervals. The validity of the assump-
tion of the proportional hazard models will be checked by
using graphical approaches or time-dependent covariates.
The interim analysis will be conducted at one and three
years after the completion of registration. If the Ethics Com-
mittee of this study concludes that the ginseng treatment is
significantly effective or that no efficacy would be expected
for further continuation of the study after examining the
interim analysis, the Ethics and Data Monitoring Commit-
tee will recommend termination of the study.
Test Sample
The samples will be provided by Wakunaga Pharmaceu-
tical Co., Ltd. (Hiroshima, Japan). Each capsule for the GI
group will contain 250 mg of the powdered red ginseng
processed from the roots of Panax ginseng C.A. Meyer culti-
vated in China and 10 mg of sucrose esters of fatty acids,
and 4 capsules (1 g of red ginseng powder) will be ingested
daily. Each capsule for the NF group will contain 250 mg
of corn starch and 10 mg of sucrose esters of fatty acids, and
4 capsules will be ingested daily.
Current Status
The first protocol was submitted to the Ethics Committee
for this study in March, 2000, and the Committee directed
to amend the protocol after their consideration. The revised
protocol was submitted to the Committee November, 2000,
and approved. Then, the protocol was submitted to the ethics
committee of each hospital for their approval. Up through
March, 2001, three ethics committees approved the study,
and the collaborator-physicians are now recruiting patients
at those hospitals.
DISCUSSION
The follow-up study showed that the incidence of HCC
was approximately 37% for 5 yr in HCV associated cirrho-
sis patients. According to the Osaka Cancer Registry, Japan,
the 5-yr relative survival rate of HCC patients in 1987 was
5.5% and their prognosis was extremely poor. The develop-
ment of procedures to prevent HCC is urgently desired.
Recently, interferon has been shown to successfully prevent
the development of HCC9 (10). However, hepatitis C virus
could not be eliminated by interferon therapy in 30% of the
patients. Moreover, interferon therapy for liver cirrhosis pa-
tients is not covered by public insurance. This suggests that
interferon therapy alone is not sufficient for HCC preven-
tion and the methods to make up this therapy are in need.
Sho-saiko-to is a well-known Kamo medicine containing
ginseng and has been shown to inhibit liver cancer develop-
ment (8). Unfortunately, Sho-saiko-to alone or in combina-
tion therapy with interferon was reported to cause a severe
side effect, interstitial pneumonia. Interstitial pneumonia is
an allergic disease and eventually leads to severe conditions.
Allergic reactions occurring in the interstitium of the lung
can be caused by medicines including Sho-saiko-to. The lym-
phocyte stimulation test frequently reveals positive reactions
in patients to scutellaria root, bupleurum root and pinellia
tuber, which are contained in Sho-saiko-to. Scutellaria root-
containing Kampo medicines such as Saibokuto, Saireito and
Rokkunshito are also reported to cause interstitial pneumo-
nia. Thus, the interstitial pneumonia induced by Sho-saiko-
to has been speculated to be mainly due to scutellaria root.
However, since Bakumondoto, which does not contain scutel-
laria root has been shown to cause interstitial pneumonia,
herbs other than scutellaria root also cause pneumonia. Gin-
S72 The Ginseng-HCC Chemopreventive Study Osaka Groupseng occasionally shows a positive reaction in the lympho-
cyte stimulation test, however, it is unlikely to cause inter-
stitial pneumonia since its historical and current uses have
not resulted in pneumonia.
Ginseng has been shown to enhance natural healing power
and to improve general conditions and non-specific com-
plaints due to the exhaustive and feverish illness through
enhancement of natural healing power. Also, ginseng has
been shown to inhibit carcinogenesis in animal models (3-
5). A recent case-control study in Korea demonstrated  the
prevention of cancer development in several organs by gin-
seng ingestion (6, 7).
According to these data, a cancer-preventive study for the
high-risk group of HCC seems warranted. Thus, scientists
of various endeavour, including epidemiologists, biochemists,
pathologists, pharmacologists, bio-statisticians, physicians
and a pharmaceutical manufacturer, have collaborated, and
collected information regarding ginseng and cancer. After
analyzing all the available informations, all members dis-
cussed in great detail the possible success of an intervention
study. In the course of discussion, Fukushima and his col-
leagues who conducted animal carcinogenesis experiments,
stated that ginseng did not increase or decrease the develop-
ment of preneoplastic lesions in the liver. Nishino et al. found
that red ginseng rather than white ginseng significantly
inhibited the development of spontaneous liver tumors in
mice. According to available data and our own studies, we
concluded that the intervention trial of ginseng on HCC
could be applicable to the high risk group. The pharma-
cokinetics and safety studies of red ginseng were conducted
using healthy volunteers from January to February, 2000.
No significant complaints or side effects due to red ginseng
intake were reported, and the bio-compliance marker for
red ginseng intake was established. After the completion of
these steps, this multi-center, double-blind, randomized,
placebo-controlled trial was designed, and is now in progress.
Researchers from various scientific fields have collaborat-
ed in the planning of this study. In the past, such a collabo-
rative study has never been conducted in Japan. Thus, we
sincerely expect good results from this study by the time of
its completion within 7 yr.
APPENDIX
The members of the Ginseng-HCC Chemopreventive
Study Osaka Group are as follows: Hideki Ishikawa, Takaichi-
ro Suzuki, Toru Otani (Osaka Medical Center for Cancer and
Cardiovascular Diseases), Taik-Koo Yun (Korea Cancer Center
Hospital), Hoyoku Nishino (Department of Biochemistry,
Kyoto Prefectural University of Medicine), Sumio Kawata
(Second Department of Internal Medicine Yamagata Uni-
versity School of Medicine), Shoji Fukushima (Department
of Pathology Osaka City University Medical School), Yuta-
ka Matsuyama (Department of Biostatistics Kyoto Univer-
sity School of Public Health), Osamu Tanaka (Institute of
Pharmaceutical Sciences, Faculty of Medicine, Hiroshima
University), Yasuharu Imai, Kazuto Fukuda (Department of
Internal Medicine, Ikeda Municipal Hospital), Masami Inada,
Yukihiko Matsuda (Department of Internal Medicine, Toyo-
naka Municipal Hospital), Iwao Yabuuchi (Department of
Internal Medicine, Otemae Hospital), Shuzo Noda (Depart-
ment of Internal Medicine, Suita Municipal Hospital), Shin-
ji Tamura (Second Department of Internal Medicine, Osaka
University Medical School), Yuichi Maeda (Department of
Internal Medicine, Kawanishi City General Hospital), Yasuhiro
Shirai (Department of Internal Medicine, Izumisano Munic-
ipal Hospital), Yoshirou Kayanoki (Department of Internal
Medicine, Izumiotsu Municipal Hospital), Hiromichi
Sumiyoshi, Toru Fuwa (Wakunaga Pharmaceutical Co., Ltd.),
Shoji Shibata (Shibata Laboratory of Natural Medicinal
Materials), Kenji Jinno (Clinical Division, National Shikoku
Cancer Center). The members of the Ethics and Data Moni-
toring Committee are as follows: Tetsuro Yamane (Depart-
ment of Surgery, Matsushita Memorial Hospital), Tosiya Sato
(Department of Epidemiology and Biostatistics Kyoto Uni-
versity School of Public Health), Yoshiyuki Watanabe (De-
partment of Social Medicine & Cultural Sciences, Research
Institute for Neurological Diseases & Geriatrics, Kyoto Pre-
fectural University of Medicine), Hiraku Takebe (Atomic
Energy Research Institute, Kinki University). The members
of  the secretariat are as follows: Ayako Nasu (Osaka Medi-
cal Center for Cancer and Cardiovascular Diseases), Takashi
Hosaka (Wakunaga Pharmaceutical Co., Ltd.).
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